Shanghai Aibo Pharmaceutical Technology Co Ltd

Primary Objectives 1) To evaluate the efficacy of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. Secondary Objectives 1) To evaluate the safety of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. Exploratory Objectives 1) To evaluate the pharmacokinetic profile of ABP1011T tablets in patients with locally advanced, unresectable, or metastatic osteosarcoma. 2) To exploratoryally investigate the relationship between biomarkers and efficacy in patients with locally advanced, unresectable, or metastatic osteosarcoma.

Primary purpose: To evaluate the effectiveness of ABP2111Na tablets after oral administration in overweight/obese participants; Secondary purpose: 1) To evaluate the safety of ABP2111Na tablets after oral administration in overweight/obese participants; 2) To evaluate the population pharmacokinetic (PK) characteristics of ABP2111Na tablets after oral administration in overweight/obese participants; 3) To explore the optimal dose of ABP2111Na tablets for the treatment of overweight/obesity; Exploratory purpose: 1) To explore the changes in pharmacodynamic-related indicators after oral administration of ABP2111Na tablets in overweight/obese participants; 2) To explore the effects of ABP2111Na tablets on fatty liver disease-related indicators in overweight/obese participants.

Study Objectives Main Study Objectives 1. Evaluate the effectiveness of ABP1019A tablets in target patients with advanced solid tumors. Secondary Study Objectives 2. Evaluate the safety of ABP1019A tablets in target patients with advanced solid tumors. Exploratory Study Objectives 3. Evaluate the population pharmacokinetic (PPK) characteristics of ABP1019A tablets in target patients with advanced solid tumors.